ArticleMedical oncology (Northwood, London, England)2026
Therapeutic exploration of combined local hyperthermia and anti-CD200 blockade therapy in the EMT6 breast cancer model.
Article in Medical oncology (Northwood, London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer remains the leading cause of cancer-related deaths among women worldwide. Combinatorial therapies are often employed to improve treatment efficacy and reduce the risk of recurrence. Hyperthermia (HT), a minimally invasive treatment, has shown potential to enhance immunotherapy outcomes. In the EMT6 breast tumor model, elevated CD200 expression is associated with tumor progression, and blockade of the CD200/CD200R signaling pathway has been reported to enhance anti-tumor immune responses. This study presents a preliminary evaluation of the therapeutic effects of local HT combined with anti-CD200 blockade in a preclinical mouse model. EMT6 tumors were established in Balb/c mice via subcutaneous inoculation. Local HT was applied on days 7, 8, and 9 post-inoculation, and anti-CD200 monoclonal antibody was administered intraperitoneally on days 7, 9, and 11. The combination therapy significantly reduced tumour progression and improved survival. Moreover, treated mice showed increased activation of CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.